Raymond James cuts Stryker stock price target on cyber incident impact – Image for illustrative purposes only (Image credits: Flickr)
Stryker Corp. navigated a significant operational hurdle in the first quarter of 2026 when a cyber incident disrupted its systems for nearly three weeks. The medical technology leader reported earnings that missed Wall Street forecasts, largely due to the late-March breach that delayed shipments and revenue recognition. Analysts responded swiftly, with Raymond James leading adjustments to reflect the prolonged effects, even as the company reaffirmed its annual targets.
The Cyber Incident That Shook Operations
On March 11, 2026, Stryker detected a cybersecurity attack targeting its Microsoft environment, prompting an immediate incident response. The breach involved a malicious file that allowed intruders to conceal their actions, though investigators found no evidence of ransomware or malware spreading beyond internal systems.[1][2]
The disruption halted order processing, manufacturing, and shipping across global facilities, affecting everything from personalized implants to routine supplies. Healthcare providers faced delays in elective procedures and product deliveries, though Stryker emphasized that patient safety remained paramount and no customer data was compromised. By early April, production resumed at full capacity, with core systems restored through round-the-clock efforts alongside experts like Palo Alto Networks Unit 42 and U.S. agencies including the FBI and CISA.
First-Quarter Earnings Fall Short of Expectations
Stryker posted first-quarter revenue of $6.02 billion, a 2.6 percent increase from the prior year but well below the $6.34 billion consensus estimate – a gap of about 5 percent. Organic sales growth registered at 2.4 percent globally, with U.S. figures at 1.9 percent and international at 3.9 percent. Adjusted earnings per share came in at $2.60, missing the anticipated $2.98, while profit rose to $745 million, or $1.93 per share, from $654 million the year before.[3][4]
Margins bore the brunt of the incident: adjusted gross margin declined 190 basis points to 63.6 percent, and operating margin fell 180 basis points to 21.1 percent. Executives attributed roughly $320 million of the revenue shortfall to deferred shipments and production halts, with varying impacts across segments – orthopedics fared better thanks to consigned inventory, while MedSurg faced steeper capital equipment delays.
Analyst Reactions: Raymond James Takes the Lead
Raymond James lowered its price target on Stryker shares to $383 from $418 while keeping an Outperform rating, citing a larger-than-expected first-quarter hit and a recovery timeline extending longer than projected. The firm described the cyber event as temporary and not fundamentally altering Stryker’s position as a top-tier medtech operator, but the EBIT margin compression of 200 basis points factored into the revision.[2]
Other firms echoed the caution. Stifel cut its target to $360 from $440, BTIG to $379 from $397, Wolfe Research to $350 from $405, and TD Cowen to $355 – all retaining Buy or equivalent ratings in most cases. The stock, trading around $303 and down 10 percent year-to-date, hovered near its 52-week low of $311, reflecting investor unease over the incident’s ripple effects.
- Raymond James: $418 → $383 (Outperform)
- Stifel: $440 → $360 (Buy)
- BTIG: $397 → $379 (Buy)
- Wolfe Research: $405 → $350 (Outperform)
- TD Cowen: $355 (Hold)
Recovery Efforts and Unchanged Full-Year Guidance
Management highlighted a “stunning and incredibly successful” rebound, with operations fully normalized by April 1 and most lost sales slated for recapture in the second half of the year. Deferred procedures and production backlogs would drive catch-up in revenue recognition during the second quarter and rescheduling in the latter half, executives explained during the earnings call. Confidence stemmed from robust demand signals, including record Mako robot installations and strong international growth, particularly in Japan.
Stryker stuck to its 2026 outlook, projecting 8 to 9.5 percent organic sales growth and adjusted EPS between $14.90 and $15.10. Pricing remained modestly positive, and tariff dynamics were expected to improve. Investments in cybersecurity had been embedded in the guidance, alongside planned launches like Shoulder on Mako and the Ortho Tech business combining robotics with instruments. The Amplitude Vascular Systems acquisition, set to close in the second quarter, would bolster peripheral vascular offerings.
Analysts pressed for details on segment-specific recovery during the call, with Raymond James inquiring about the new Smart Hospital platform, which integrates Vocera and Care.ai technologies despite the disruptions. Executives noted healthy hospital capital spending and an elevated order backlog as tailwinds.
As Stryker pushes forward, the episode underscores the vulnerabilities in medtech supply chains amid rising cyber threats. Investors weigh the company’s proven execution against short-term uncertainties, with the stock’s valuation – flagged as undervalued by some metrics – offering potential entry points for those betting on a swift return to form. The broader sector now eyes enhanced defenses, knowing that operational resilience defines long-term winners in healthcare.